Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone

20148 citationsJournal Articlegold Open Access

Authors

Τushar Garimella · Bristol-Myers Squibb (United States)

Reena Wang · Bristol-Myers Squibb (United States)

Wen‐Lin Luo · Bristol-Myers Squibb (United States)

Philip Wastall · Bristol-Myers Squibb (United States)

Hamza Kandoussi · Bristol-Myers Squibb (United States)

Michael DeMicco · Anaheim Clinical Trials

Douglas Bruce

Abstract

Steady-state administration of DCV 60mg QD had no clinically meaningful effect on the PK of MET or BUP/NLX and was generally well-tolerated, suggesting that no dose adjustments will be required.

Topics & Keywords

Hepatitis C virus research Diabetes Treatment and Management Pharmacogenetics and Drug Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the International AIDS Society

Volume 17, Issue 4S3, pp. 19628-19628

DOI: 10.7448/ias.17.4.19628

Field-Weighted Citation Impact: 1.00